Nluc Reporter Cell Line - KPC

The KPC cell line is derived from pancreatic ductal adenocarcinoma (PDAC) and is genetically engineered to carry key mutations in the KRAS and TP53 genes. These mutations are highly prevalent in human pancreatic cancer and drive tumor initiation, progression, and drug resistance. KRAS mutations (typically G12D) constitutively activate oncogenic signaling pathways, while TP53 mutations disrupt cell cycle regulation and apoptosis. KPC cells are typically isolated from genetically modified mouse models but can also be used for in vitro studies. They exhibit aggressive growth, invasiveness, and resistance to chemotherapy, making them a clinically relevant model for studying pancreatic cancer biology and testing novel therapies. Their molecular characteristics closely resemble human PDAC, allowing researchers to investigate tumor microenvironment interactions, metastatic mechanisms, and immune evasion strategies.

The Nluc reporter cell line-KPC integrates NanoLuc luciferase (Nluc) into KPC cells, enabling highly sensitive bioluminescent imaging for real-time monitoring of tumor dynamics. Compared to traditional luciferases, this reporter system leverages Nluc''s superior brightness and stability to quantitatively track tumor growth, metastasis, and treatment response in vivo with extremely low background noise. Applications include high-throughput drug screening, where bioluminescent signals can rapidly indicate compound efficacy or resistance mechanisms. In preclinical studies, it facilitates longitudinal assessment of immunotherapy responses, tumor-stroma interactions, and metastatic dissemination in orthotopic or transgenic models. Furthermore, this cell line supports in vitro analyses such as organoid co-cultures and signaling pathway mechanism studies. Its non-destructive imaging capabilities reduce the number of experimental animals while providing spatiotemporal resolution of disease progression, thus accelerating translational research in pancreatic cancer treatment.